New scan seeks to spot deadliest prostate cancer
NCT ID NCT05245006
Summary
This early-stage study is testing a new imaging agent for PET scans in men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if this new tracer can better detect and locate cancer tumors by targeting a specific protein (CD46) found on aggressive cancer cells. Researchers hope this improved imaging will help guide future treatments for the most difficult-to-treat forms of the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.